Noradrenaline — Clinical Reference

Overview

Introduction to Noradrenaline

⬡Pharmacology

Noradrenaline (norepinephrine) is an endogenous catecholamine acting as both a neurotransmitter and circulating hormone. It is the primary sympathetic neurotransmitter.

Primary action: α₁-adrenoceptor agonist → vasoconstriction
Secondary action: β₁-adrenoceptor agonism → modest positive inotropy
Net haemodynamic effect: ↑ SVR, ↑ MAP, minimal heart rate change
Plasma half-life: approximately 2–3 minutes
Metabolism: MAO (neuronal reuptake) and COMT (extraneuronal)
Elimination: primarily hepatic and renal

⬡Clinical Indications

Noradrenaline is the first-line vasopressor for septic shock per the Surviving Sepsis Campaign (SSC 2021) guidelines, recommended as a strong, evidence-based intervention.

Septic shock (first-line, strong recommendation)
Vasodilatory / distributive shock (other causes)
Adjunct in cardiogenic shock with systemic vasodilation
Post-operative hypotension refractory to fluid challenge

Key Clinical Points Standard ampule: 4 mg / 2 ml (2 mg/ml) · First-line over dopamine (SSC 2021) · Target MAP ≥ 65 mmHg · Central venous access required for concentrations > 80 mcg/ml · Avoid peripheral administration of concentrated solutions

✓Advantages over Dopamine

Lower arrhythmia risk (12.4% vs 24.1%, SOAP II)
More predictable, linear dose-response
Does not stimulate dopaminergic receptors at clinical doses
No evidence of "low-dose renal protection" with dopamine (SSC guideline)
Extensive evidence base across multiple RCTs and meta-analyses

△Adverse Effects & Cautions

Tissue necrosis if extravasation occurs (use central line)
↓ Splanchnic and mesenteric blood flow at high doses
Digital / limb ischaemia with prolonged high-dose infusion
Contraindicated in uncorrected hypovolaemia
Can worsen hypertension — monitor continuously
Caution in severe peripheral vascular disease

⬡Surviving Sepsis Campaign 2021 — Vasopressor Recommendations

Noradrenaline as first-line vasopressor for septic shock (strong recommendation)
Add vasopressin (0.03 U/min fixed dose) to noradrenaline rather than escalating dose, when MAP target not met (weak recommendation, moderate evidence)
Add adrenaline to noradrenaline as a second-line agent when target MAP not achieved (weak recommendation, low quality evidence)
Do not use low-dose dopamine for renal protection (strong recommendation, high quality evidence)
Target MAP ≥ 65 mmHg during initial resuscitation (strong recommendation)
Suggest individualising MAP targets in patients with chronic hypertension or known atherosclerotic disease (weak recommendation)
Early initiation of vasopressors — do not delay to complete fluid loading

Reference Tables

Noradrenaline Dosage Tables — Syringe Pump

Preparation Standard Ampule: 4 mg / 2 ml (2 mg/ml) · Diluent: 5% Dextrose (D5W) or 0.9% NaCl · Total syringe volume: 50 ml · All infusions below require a dedicated central venous lumen. A note on formulations: in many countries noradrenaline is supplied as the tartrate salt; confirm your local ampule concentration before preparation.

Low dose Moderate dose High dose — consider adjunct vasopressor

Single Strength — 1 Ampule

4 mg + D5W → 50 ml
Concentration: 80 mcg/ml

mcg/min = ml/hr × 1.33

ml/hr	mcg/min	mcg/kg/min (70 kg)	Context
1	1.3	0.019	Initiation
2	2.7	0.038	Low support
3	4.0	0.057	Low–moderate
4	5.3	0.076	Moderate
5	6.7	0.095	Moderate
7	9.3	0.133	Higher
10	13.3	0.190	Significant
15	20.0	0.286	High — escalate

Double Strength — 2 Ampules

8 mg + D5W → 50 ml
Concentration: 160 mcg/ml

mcg/min = ml/hr × 2.67

ml/hr	mcg/min	mcg/kg/min (70 kg)	Context
1	2.7	0.038	Low support
2	5.3	0.076	Moderate
3	8.0	0.114	Moderate
4	10.7	0.152	Higher
5	13.3	0.190	Significant
6	16.0	0.229	High
8	21.3	0.305	Escalate
10	26.7	0.381	Add vasopressin

Quadruple Strength — 4 Ampules

16 mg + D5W → 50 ml
Concentration: 320 mcg/ml

mcg/min = ml/hr × 5.33

ml/hr	mcg/min	mcg/kg/min (70 kg)	Context
1	5.3	0.076	Moderate
2	10.7	0.152	Higher
3	16.0	0.229	High
4	21.3	0.305	Escalate
5	26.7	0.381	Add vasopressin
6	32.0	0.457	Max range
8	42.7	0.610	Refractory shock
10	53.3	0.762	Crisis — consider ECMO

Clinical Notes

Starting dose: 0.05–0.1 mcg/kg/min (SSC 2021)
Titrate: increment by 0.05–0.1 mcg/kg/min every 3–5 min
Add vasopressin at 0.03 U/min when dose ≥ 0.25–0.5 mcg/kg/min
Maximum: generally < 1 mcg/kg/min before escalation
Central line: mandatory for concentrations > 80 mcg/ml
Monitoring: continuous arterial BP, urine output, peripheral perfusion
Weaning: reduce by 25–50% increments every 30–60 min
Compatibility: D5W or 0.9% NaCl; avoid bicarbonate/alkaline solutions
Stability: use within 24 h of preparation; protect from light
Note: mcg/kg/min values for 70 kg reference patient only — recalculate for actual weight

Calculations

Dose Calculation — Step by Step

Step 01 Understanding the Ampule

Standard Ampule (most countries) 4 mg noradrenaline base · 2 ml volume · Concentration = 2 mg/ml = 2,000 mcg/ml

Ampule content (mcg) = 4 mg × 1000 = 4,000 mcg per ampule

Important — Formulation Clarification Some countries supply noradrenaline as the tartrate salt (e.g., 8 mg noradrenaline tartrate ≈ 4 mg noradrenaline base). Always verify your local ampule labelling. These tables use noradrenaline base equivalent.

Step 02 Calculating Final Concentration in a 50 ml Syringe

Dilute the required number of ampules with D5W or 0.9% NaCl to reach a total syringe volume of 50 ml.

Single (1 ampule)
4,000 mcg ÷ 50 ml
= 80 mcg/ml

Double (2 ampules)
8,000 mcg ÷ 50 ml
= 160 mcg/ml

Quadruple (4 ampules)
16,000 mcg ÷ 50 ml
= 320 mcg/ml

General Formula:
Concentration (mcg/ml) = (Number of ampules × 4,000 mcg) ÷ 50 ml

Step 03 Converting Pump Rate (ml/hr) to Dose (mcg/min)

Core Formula:
mcg/min = (ml/hr × concentration in mcg/ml) ÷ 60

Why divide by 60? Because ml/hr × mcg/ml gives mcg per hour — divide by 60 to convert to mcg per minute.

Worked Example — Double Strength, 70 kg Patient Preparation: 2 ampules (8 mg) in D5W to 50 ml → 160 mcg/ml

Pump set at: 5 ml/hr
mcg/hr = 5 ml/hr × 160 mcg/ml = 800 mcg/hr
mcg/min = 800 ÷ 60 = 13.3 mcg/min
mcg/kg/min = 13.3 ÷ 70 = 0.19 mcg/kg/min

Step 04 Quick Conversion Factors

To avoid manual calculation at the bedside, use these fixed multipliers:

Preparation	Conc. (mcg/ml)	Factor	Quick formula	Derivation
1 ampule (single)	80	1.33	mcg/min = ml/hr × 1.33	80 ÷ 60
2 ampules (double)	160	2.67	mcg/min = ml/hr × 2.67	160 ÷ 60
4 ampules (quadruple)	320	5.33	mcg/min = ml/hr × 5.33	320 ÷ 60

Reverse Calculation — Target Dose to Pump Rate If you know the required dose in mcg/min, divide by the conversion factor to get ml/hr.
Example: Target 10 mcg/min on double strength → 10 ÷ 2.67 = 3.75 ml/hr

Key Trials

Clinical Evidence Base

SOAP II — Comparison of Dopamine and Norepinephrine in the Treatment of Shock

De Backer D et al. SOAP II Investigators. N Engl J Med. 2010;362(9):779–789.

2010 · N Engl J Med

Design: Multicentre, randomised, double-blind trial. n = 1,679 (858 dopamine, 821 norepinephrine). All types of shock included (60% septic, 17% cardiogenic, 16% hypovolaemic).

Primary outcome — 28-day mortality: 52.5% (dopamine) vs 48.5% (norepinephrine) OR 1.17 (95% CI 0.97–1.42); p = 0.10 — No significant difference

Arrhythmic events: 24.1% (dopamine) vs 12.4% (norepinephrine) — p < 0.001, highly significant reduction with norepinephrine

Cardiogenic shock subgroup: Dopamine associated with significantly higher 28-day mortality in the 280 cardiogenic shock patients (p = 0.03). No significant difference in the 1,044 septic shock patients (p = 0.19).

Conclusion: No difference in overall mortality, but dopamine carries significantly greater risk of arrhythmias and appears harmful in cardiogenic shock. This safety advantage established norepinephrine as the preferred agent.

Framing clarification: SOAP II did not show norepinephrine was superior in mortality terms for the overall population. Its importance lies in demonstrating that dopamine is less safe — particularly its arrhythmia burden and cardiogenic shock signal — rather than norepinephrine having a direct mortality benefit. Subsequent Bayesian reanalysis (Vincent et al., 2024) found dopamine consistently disfavoured across all subgroups.

VASST — Vasopressin versus Norepinephrine in Patients with Septic Shock

Russell JA et al. VASST Investigators. N Engl J Med. 2008;358(9):877–887.

2008 · N Engl J Med

Design: Multicentre, randomised, double-blind trial. n = 778 (396 vasopressin, 382 norepinephrine). Patients already receiving ≥ 5 mcg/min norepinephrine were randomised to add fixed-dose vasopressin (0.01–0.03 U/min) vs add additional norepinephrine — both groups were on catecholamines. This is effectively a vasopressin adjunct trial, not a direct head-to-head substitution.

28-day mortality (vasopressin vs norepinephrine): 35.4% vs 39.3%; p = 0.26 — No significant difference

90-day mortality: 43.9% vs 49.6%; p = 0.11 — No significant difference

Less severe septic shock subgroup (norepinephrine < 15 mcg/min at entry): 26.5% (vasopressin) vs 35.7% (norepinephrine); p = 0.05 — Trend favouring vasopressin (hypothesis-generating only; heterogeneity test not significant p = 0.10)

Serious adverse events: 10.3% vs 10.5%; p = 1.00 — No difference

Vasopressin sparing effect: Vasopressin group required significantly less norepinephrine (catecholamine-sparing effect confirmed)

Design note: VASST tested the addition of vasopressin to background norepinephrine therapy, not vasopressin as a standalone replacement. The trial was underpowered (expected 60% mortality; observed 35–39%), making a type II error possible. The SSC 2021 guideline translates this into a recommendation to add vasopressin 0.03 U/min as a second agent to reduce norepinephrine dose.

VANISH — Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Septic Shock

Gordon AC et al. JAMA. 2016;316(5):509–518.

2016 · JAMA

Design: 2×2 factorial, randomised, double-blind. n = 409. Vasopressin (up to 0.06 U/min) vs norepinephrine as initial vasopressor. Primary outcome: kidney failure-free days.

No significant difference in kidney failure-free days, 28-day mortality, or other organ outcomes between vasopressin and norepinephrine arms.

RRT need: 25.4% (vasopressin) vs 35.3% (norepinephrine); p = 0.007 — significant reduction in RRT with vasopressin, but was not the pre-specified primary endpoint and should be interpreted with caution.

Early Noradrenaline Initiation in Septic Shock — Meta-Analytic Evidence

Shi R et al. Crit Care. 2025;29(1):182 · Ahn C et al. Chest. 2024 · Li Y et al. J Intensive Med. 2025;5(2):160–166.

2024–2025

Summary of emerging evidence: Multiple meta-analyses and prospective cohort studies now suggest that earlier initiation of noradrenaline (within 1 hour of septic shock diagnosis) is associated with:

Lower 28-day mortality compared with delayed initiation

Faster achievement of MAP ≥ 65 mmHg

Reduced 24-hour fluid resuscitation volumes (potential fluid-sparing effect)

Higher early lactate clearance rates

Evidence quality note: This emerging body of evidence is predominantly from observational studies and meta-analyses of heterogeneous trials. Randomised evidence on the optimal timing of vasopressor initiation (including VASOSHOCK) is ongoing. Current SSC 2021 guidelines support early vasopressor use but acknowledge the timing evidence as moderate quality.

Surviving Sepsis Campaign — Guideline Evolution (2004–2021)

Rhodes A et al. Intensive Care Med. 2017 (2016 guidelines) · Evans L et al. Intensive Care Med. 2021;47:1181–1247.

Guidelines

2004: First SSC guidelines — dopamine and noradrenaline listed as equivalent first-line vasopressors

2008: Both dopamine and noradrenaline recommended; growing concern about dopamine safety

2012: Post-SOAP II — noradrenaline preferred over dopamine for most patients

2016: Noradrenaline formally established as first-line vasopressor (strong recommendation)

2021: Noradrenaline maintained as first-line; emphasis on early initiation, vasopressin as second-line adjunct (0.03 U/min fixed dose), and individualised MAP targets

History

Evolution of Noradrenaline in Critical Care

1901

Adrenaline isolated by Jokichi Takamine

The discovery of adrenaline opened the era of catecholamine pharmacology and vasopressor therapy.

1946

Ulf von Euler identifies noradrenaline as the sympathetic neurotransmitter

Von Euler demonstrated that noradrenaline, not adrenaline, is the primary transmitter released at postganglionic sympathetic nerve terminals. This work later contributed to his 1970 Nobel Prize in Physiology or Medicine.

1970s

Early clinical use of noradrenaline in vasodilatory shock

Initial clinical applications emerged, though concerns about renal and splanchnic vasoconstriction limited its adoption. Dopamine — with its perceived "renal-protective" low-dose properties — remained widely preferred despite limited evidence for this effect.

1991

First ACCP/SCCM consensus definitions for sepsis and septic shock

Publication of the American College of Chest Physicians / Society of Critical Care Medicine consensus. Dopamine was the dominant vasopressor of the era.

2001

EGDT trial — Rivers et al.

The landmark early goal-directed therapy trial (N Engl J Med) established the importance of protocolised resuscitation including vasopressor use for MAP ≥ 65 mmHg, shaping sepsis management for the subsequent decade.

2004

First Surviving Sepsis Campaign guidelines published

SSC 2004 recommended dopamine or noradrenaline as first-line vasopressors with no preference, reflecting the evidence available at the time.

2008

VASST trial published — vasopressin vs norepinephrine in septic shock

Russell et al. (N Engl J Med) showed no mortality benefit of adding vasopressin vs adding norepinephrine. A subgroup with less severe shock showed a trend favouring vasopressin. This established vasopressin's role as a catecholamine-sparing adjunct rather than a primary agent.

2010

SOAP II trial — turning point for vasopressor selection

De Backer et al. (N Engl J Med) demonstrated that dopamine carried significantly higher arrhythmia rates (24.1% vs 12.4%, p < 0.001) and was associated with higher mortality in cardiogenic shock. This profoundly changed prescribing practice in favour of noradrenaline.

2012–2016

Noradrenaline established as first-line vasopressor

SSC 2012 and 2016 guidelines formalised noradrenaline preference. The 2016 guidelines explicitly stated noradrenaline as the first-choice vasopressor (strong recommendation, moderate evidence), and discouraged dopamine except in selected patients.

2016

VANISH trial published

Gordon et al. (JAMA) compared vasopressin vs norepinephrine as the initial vasopressor, finding no difference in kidney failure-free days, though the vasopressin group needed less renal replacement therapy.

2016

Sepsis-3 definitions

Singer et al. (JAMA) published the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), redefining septic shock as sepsis with vasopressor requirement to maintain MAP ≥ 65 mmHg and serum lactate > 2 mmol/L despite adequate fluid resuscitation.

2021

SSC 2021 guidelines — consolidation and early initiation

Evans et al. maintained noradrenaline as first-line, added vasopressin (0.03 U/min) as the preferred second agent, emphasised early vasopressor initiation, and recommended against delaying vasopressors to complete fluid loading.

2024–2025

Emerging evidence for ultra-early initiation

Multiple meta-analyses (Shi et al. 2025, Ahn et al. 2024) suggest earlier initiation of noradrenaline (< 1 hour of shock diagnosis) may reduce mortality and total fluid administration. Ongoing RCTs (VASOSHOCK and others) continue to investigate optimal timing strategies.

Literature

References

De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789. DOI: 10.1056/NEJMoa0907118
Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–887. DOI: 10.1056/NEJMoa067373
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Møller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247. DOI: 10.1007/s00134-021-06506-y
Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Prevost AT, Brett SJ; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509–518. DOI: 10.1001/jama.2016.10485
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Miller RR, Moreno R, Morley J, Timsit JF, Trzeciak S, Dellinger RP. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. DOI: 10.1007/s00134-017-4683-6
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287
Shi R, Braïk R, Monnet X, Teboul JL, Hamzaoui O. Early norepinephrine for patients with septic shock: an updated systematic review and meta-analysis with trial sequential analysis. Crit Care. 2025;29(1):182. DOI: 10.1186/s13054-025-05170-8
Ahn C, Yu G, Shin TG, Cho Y, Park S, Suh GY. Comparison of early and late norepinephrine administration in patients with septic shock: a systematic review and meta-analysis. Chest. 2025;167(1):171–183. DOI: 10.1016/j.chest.2024.08.012
Li Y, Zhang D, Li H, Wang Y, Zhang D. Effect of timing of norepinephrine administration on prognosis of patients with septic shock: a prospective cohort study. J Intensive Med. 2025;5(2):160–166. DOI: 10.1016/j.jointm.2024.09.003
Vincent JL, De Backer D, Wiedermann CJ, Fukushima S, Yamakawa K, Antonelli M, Landoni G. Exploration of different statistical approaches in the comparison of dopamine and norepinephrine in the treatment of shock: SOAP II. Crit Care. 2024;28(1):371. DOI: 10.1186/s13054-024-05016-9
Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015;10(8):e0129305. DOI: 10.1371/journal.pone.0129305
Ospina-Tascón GA, Hernandez G, Alvarez I, Calderón-Tapia LE, Manzano-Nunez R, Sánchez-Ortiz AI, Quiñones E, Madriñán HJ, Valencia JD, Aldecoa C, De Backer D, García AF. Effects of very early start of norepinephrine in patients with septic shock: a propensity score-based analysis. Crit Care. 2020;24(1):52. DOI: 10.1186/s13054-020-2756-6
Morales S, Wendel-Garcia PD, Ibarra-Estrada M, García-Salcido R, Aguirre-Avalos G, Escobar-Ortiz L, Teboul JL. The impact of norepinephrine dose reporting heterogeneity on mortality prediction in septic shock patients. Crit Care. 2024;28(1):216. DOI: 10.1186/s13054-024-05006-x
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368–1377. DOI: 10.1056/NEJMoa010307
Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009;24(5):293–316. DOI: 10.1177/0885066609340743
Hamzaoui O, Georger JF, Monnet X, Ksouri H, Maizel J, Richard C, Teboul JL. Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. Crit Care. 2010;14(4):R142. DOI: 10.1186/cc9207